|
Consolidated Statements of Operations (USD $)
|
3 Months Ended | |
|---|---|---|
|
Mar. 31, 2015
|
Mar. 31, 2014
|
|
| Revenues [Abstract] | ||
| Lymphoseek sales revenue | $ 1,835,422us-gaap_SalesRevenueNet | $ 626,631us-gaap_SalesRevenueNet |
| Lymphoseek license revenue | 83,333us-gaap_LicensesRevenue | 0us-gaap_LicensesRevenue |
| Grant and other revenue | 189,701us-gaap_RevenueFromGrants | 125,173us-gaap_RevenueFromGrants |
| Total revenue | 2,108,456us-gaap_Revenues | 751,804us-gaap_Revenues |
| Cost of goods sold | 449,057us-gaap_CostOfGoodsSold | 193,220us-gaap_CostOfGoodsSold |
| Gross profit | 1,659,399us-gaap_GrossProfit | 558,584us-gaap_GrossProfit |
| Operating expenses: | ||
| Research and development | 3,981,288us-gaap_ResearchAndDevelopmentExpense | 5,226,794us-gaap_ResearchAndDevelopmentExpense |
| Selling, general and administrative | 5,494,168navb_SellingGeneralandAdministrativeExpenseIncludingDepreciationandAmortization | 3,910,833navb_SellingGeneralandAdministrativeExpenseIncludingDepreciationandAmortization |
| Total operating expenses | 9,475,456us-gaap_OperatingExpenses | 9,137,627us-gaap_OperatingExpenses |
| Loss from operations | (7,816,057)us-gaap_OperatingIncomeLoss | (8,579,043)us-gaap_OperatingIncomeLoss |
| Other income (expense): | ||
| Interest expense, net | (966,576)us-gaap_InterestIncomeExpenseNet | (937,045)us-gaap_InterestIncomeExpenseNet |
| Equity in loss of R-NAV, LLC | (262,227)us-gaap_IncomeLossFromEquityMethodInvestments | 0us-gaap_IncomeLossFromEquityMethodInvestments |
| Change in fair value of financial instruments | 1,727,103navb_ChangeinFairValueofFinancialInstruments | 392,483navb_ChangeinFairValueofFinancialInstruments |
| Loss on extinguishment of debt | 0us-gaap_GainsLossesOnExtinguishmentOfDebt | (2,610,196)us-gaap_GainsLossesOnExtinguishmentOfDebt |
| Other, net | 26,532us-gaap_OtherNonoperatingIncomeExpense | (6,752)us-gaap_OtherNonoperatingIncomeExpense |
| Total other income (expense), net | 524,832navb_NonoperatingIncomeExpenseIncludingEquityMethodInvestments | (3,161,510)navb_NonoperatingIncomeExpenseIncludingEquityMethodInvestments |
| Net loss | (7,291,225)us-gaap_NetIncomeLoss | (11,740,553)us-gaap_NetIncomeLoss |
| Net loss attributable to noncontrolling interest | (100)us-gaap_NetIncomeLossAttributableToNoncontrollingInterest | 0us-gaap_NetIncomeLossAttributableToNoncontrollingInterest |
| Deemed dividend on beneficial conversion feature of MT Preferred Stock | (46,000)navb_DividendPreferredStockDeemedDividendUponConversion | 0navb_DividendPreferredStockDeemedDividendUponConversion |
| Net loss attributable to common stockholders | $ (7,337,125)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic | $ (11,740,553)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic |
| Loss per common share (basic and diluted) USD per share | $ (0.05)us-gaap_EarningsPerShareBasicAndDiluted | $ (0.08)us-gaap_EarningsPerShareBasicAndDiluted |
| Weighted average shares outstanding (basic and diluted) shares | 149,794,331us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted | 144,783,351us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted |
| X | ||||||||||
|
- Definition
The change in fair value of financial instruments No definition available.
|
| X | ||||||||||
|
- Definition
Dividend, Preferred Stock, Deemed Dividend Upon Conversion No definition available.
|
| X | ||||||||||
|
- Definition
Nonoperating Income (Expense), Including Equity Method Investments No definition available.
|
| X | ||||||||||
|
- Definition
Selling, General and Administrative Expense, Including Depreciation and Amortization No definition available.
|
| X | ||||||||||
|
- Definition
Total costs related to goods produced and sold during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. No definition available.
|
| X | ||||||||||
|
- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net amount of operating interest income (expense). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|